CosmosID Announces Partnership with QIAGEN for Microbial Analysis

Tools

CosmosID Announces Partnership with QIAGEN for Microbial Analysis

Rockville, MD, February 2, 2016 - CosmosID, a leading genomic big data company, today announced a partnership with QIAGEN (NASDAQ:QGEN) to launch its metagenomics analysis platform in QIAGEN's CLC Genomics Workbench. This will complete the comprehensive metagenomics application offered in QIAGEN's microbial genomics solution.  CosmosID will enable QIAGEN's customers to employ shotgun metagenomics and microbiome analysis for fields such as infectious disease, animal health, agriculture, environmental, and food safety.

By adding CosmosID's platform to the CLC Genomics workbench, researchers will be able to rapidly profile microbial communities from whole genome shotgun data, and determine their relative abundance. CosmosID's platform identifies to strain level by placement on a phylogenetic tree and allows comparative analyses of datasets employing heat maps and principal component analysis.

"Researchers running metagenomic, microbial and other applications often need to rely on complicated data analysis tools from different sources", says Laura Furmanski, Senior Vice President of QIAGEN Bioinformatics business area. "The addition of CosmosID expands the range of metagenomics applications that QIAGEN customers can access in our single, user-friendly NGS data interpretation platform."

Chris Mason, Associate Professor in Genetics from Weil Cornell Medical School said, "I have explored the microbiome of everything from the NY subway to outer space and the software analysis component is critically important. CosmosID provides a robust tool for the quantification and detection of microorganisms and antimicrobial resistance markers and we are actively using it for onsite in situ diagnostics."

In the agricultural space, CosmosID's microbiome analysis can be used for increased crop production and better plant performance in harsh or changing environmental conditions. For animal health applications, the technology can support disease diagnostics and outbreak surveillance. Additionally, food safety can be improved through rapid and accurate detection of both common and novel food borne pathogens. With a targeted database for hospital acquired infections (HAIs), hospitals can better monitor, prevent and predict HAI outbreaks.

Rita Colwell, Founder and Chair, says, "As a pioneer in the field of microbial ecology, I am very familiar with the need to understand microbial community structure and function. CosmosID developed an accurate, reproducible system that provides actionable identification of bacteria, viruses, fungi, and parasites, literally within minutes, using DNA sequencing."

Email jon.ryan@cosmosid.com for additional information.

About CosmosID
CosmosID®, based in Rockville, Maryland, is a genomics big data company focused on rapid identification of microorganisms for molecular diagnostics, public health, food safety, agriculture, and environmental applications. The CosmosID platform uses proprietary sequence analysis algorithms to accurately profile all microorganisms in a metagenomic sample employing next-generation DNA sequencing.  CosmosID was founded in 2008 by Dr. Rita Colwell, former director of the National Science Foundation and currently Distinguished University Professor at the University of Maryland and Johns Hopkins University. To learn more please visit www.cosmosid.com.

About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2015, QIAGEN employed approximately 4,500 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.